Common Contracts
13 similar Underwriting Agreement contracts by Applied Dna Sciences Inc, Global Mofy Metaverse LTD, Accelerated Pharma, Inc., others
GLOBAL MOFY METAVERSE LIMITED ORDINARY SHARES, PAR VALUE US$0.000002 PER SHARE UNDERWRITING AGREEMENTUnderwriting Agreement • March 22nd, 2023 • Global Mofy Metaverse LTD • Services-computer programming, data processing, etc. • New York
Global Mofy Metaverse Limited, an exempted company incorporated in the Cayman Islands. (the “Company”), proposes to sell to the underwriters named in Schedule I (the “Underwriters”) to this agreement (the “Agreement”) for which Maxim Group LLC is acting as representative (in such capacity, the “Representative”) an aggregate of [●] ordinary shares, par value $0.000002 per share (“Ordinary Shares”) of the Company (the “Firm Shares”). In addition, the Company proposes to grant to the Underwriters an option to purchase up to an aggregate of (i) [●] additional Ordinary Shares (the “Option Shares” and collectively with the Firm Shares, the “Securities”) The offering and sale of the Securities contemplated by this Agreement is referred to herein as the “Offering”.
GLOBAL MOFY METAVERSE LIMITED ORDINARY SHARES, PAR VALUE US$0.000002 PER SHARE UNDERWRITING AGREEMENTUnderwriting Agreement • February 7th, 2023 • Global Mofy Metaverse LTD • Services-computer programming, data processing, etc. • New York
Global Mofy Metaverse Limited, an exempted company incorporated in the Cayman Islands. (the “Company”), proposes to sell to the underwriters named in Schedule I (the “Underwriters”) to this agreement (the “Agreement”) for which Maxim Group LLC is acting as representative (in such capacity, the “Representative”) an aggregate of [●] ordinary shares, par value $0.000002 per share (“Ordinary Shares”) of the Company (the “Firm Shares”). In addition, the Company proposes to grant to the Underwriters an option to purchase up to an aggregate of (i) [●] additional Ordinary Shares (the “Option Shares” and collectively with the Firm Shares, the “Securities”) The offering and sale of the Securities contemplated by this Agreement is referred to herein as the “Offering”.
ORDINARY SHARES, NOMINAL VALUE NIS 0.01 PER SHARE UNDERWRITING AGREEMENTUnderwriting Agreement • September 30th, 2022 • Gamida Cell Ltd. • Biological products, (no disgnostic substances) • New York
Gamida Cell Ltd., a limited liability company organized under the laws of the State of Israel (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell an aggregate of 12,905,000 shares (the “Firm Shares”) of the Company’s ordinary shares with a nominal value of New Israeli Shekel (“NIS”) 0.01 per share (the “Ordinary Shares”), to the several underwriters (collectively, the “Underwriters”) named in Schedule I to this agreement (this “Agreement”), for whom Piper Sandler & Co. is acting as a representative (the “Representative”). The Company has also agreed to grant to the Underwriters an option (the “Option”) to purchase up to an additional 1,935,750 ordinary shares of the Company (the “Option Shares”) on the terms set forth in Section 1(b) hereof. The Firm Shares and the Option Shares are hereinafter collectively referred to as the “Shares.”
ACCELERATED PHARMA, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • April 26th, 2017 • Accelerated Pharma, Inc. • Pharmaceutical preparations • New York
SYSOREX GLOBAL HOLDINGS CORP. 5,250,000 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • September 25th, 2015 • Sysorex Global Holdings Corp. • Services-computer programming services • California
1,480,000 Shares Dipexium Pharmaceuticals, Inc. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • June 25th, 2015 • Dipexium Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Dipexium Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions contained herein, to sell to you and the other underwriters named on Schedule I to this Agreement (the “Underwriters”), for whom you are acting as Representative (the “Representative”), an aggregate of 1,480,000 shares (the “Firm Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”). The respective amounts of the Firm Shares to be purchased by each of the several Underwriters are set forth opposite their names on Schedule I hereto. In addition, the Company proposes to grant to the Underwriters an option to purchase up to an additional 222,000 shares (the “Option Shares”) of Common Stock from the Company for the purpose of covering over-allotments in connection with the sale of the Firm Shares. The Firm Shares and the Option Shares are collectively referred to herein as the “Shares.”
Shares of Common Stock and ______ Warrants to Purchase Shares of Common Stock APPLIED DNA SCIENCES, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • November 12th, 2014 • Applied Dna Sciences Inc • Services-miscellaneous business services • New York
Applied DNA Sciences, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions contained herein, (this “Agreement”), to sell to you and the other underwriters named on Schedule I to this Agreement (the “Underwriters”), for whom Maxim Group LLC (“Maxim”) is acting as Representative (the “Representative,” “you” or similar terminology), an aggregate of _______ shares of the Company’s common stock, $0.001 par value per share (the “Common Stock”), and ______ warrants (the “Warrants”) with the right to purchase one share of Common Stock (together, “Securities”). The respective numbers of Securities to be purchased by each of the several Underwriters are set forth opposite their names on Schedule I hereto. In addition, the Company proposes to grant to the Underwriters an option to purchase up to an additional _______ shares of Common Stock (the “Option Shares”) and up to an additional _______ Warrants (the “Option Warrants”) from the Company for the purpose
Shares of Common Stock and ______ Warrants to Purchase Shares of Common Stock APPLIED DNA SCIENCES, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • October 30th, 2014 • Applied Dna Sciences Inc • Services-miscellaneous business services • New York
Applied DNA Sciences, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions contained herein, (this “Agreement”), to sell to you and the other underwriters named on Schedule I to this Agreement (the “Underwriters”), for whom Maxim Group LLC (“Maxim”) is acting as Representative (the “Representative,” “you” or similar terminology), an aggregate of _______ shares of the Company’s common stock, $0.001 par value per share (the “Common Stock”), and ______ warrants (the “Warrants”) with the right to purchase one share of Common Stock (together, “Securities”). The respective numbers of Securities to be purchased by each of the several Underwriters are set forth opposite their names on Schedule I hereto. In addition, the Company proposes to grant to the Underwriters an option to purchase up to an additional _______ shares of Common Stock (the “Option Shares”) and up to an additional _______ Warrants (the “Option Warrants”) from the Company for the purpose
WIDEPOINT CORPORATION 6,896,552 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • October 23rd, 2014 • Widepoint Corp • Services-computer integrated systems design • California
•] SHARES TRUNKBOW INTERNATIONAL HOLDINGS LIMITED UNDERWRITING AGREEMENTUnderwriting Agreement • January 6th, 2011 • Trunkbow International Holdings LTD • Services-prepackaged software • New York
•] SHARES CHINA CERAMICS CO., LTD. UNDERWRITING AGREEMENTUnderwriting Agreement • November 9th, 2010 • China Ceramics Co., LTD • Structural clay products • New York
3,333,333 Shares MICROVISION, INC. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • November 27th, 2009 • Microvision Inc • Electronic components, nec • New York
Microvision, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions contained herein, to sell to you and the other underwriters named on Schedule I to this Agreement (the “Underwriters”), for whom you are acting as Representative (the “Representative”), an aggregate of 3,333,333 shares (the “Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”). The respective amounts of the Shares to be purchased by each of the several Underwriters are set forth opposite their names on Schedule I hereto.
Shares of Common Stock SORL AUTO PARTS, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • November 15th, 2006 • SORL Auto Parts Inc • Retail-hobby, toy & game shops • New York
SORL Auto Parts, Inc., a corporation organized and existing under the laws of Delaware (the “Company”), confirms its agreement, subject to the terms and conditions set forth herein, with each of the underwriters listed on Exhibit A hereto (collectively, the “Underwriters”), for whom Maxim Group LLC and Chardan Capital Markets, LLC are acting as representatives (in such capacity, individually and collectively, the “Representatives”), to sell and issue to the Underwriters an aggregate of _________ shares (the “Firm Shares”) of its common stock, par value $0.002 per share (the “Common Stock”). The Shares are more fully described in the Registration Statement and Prospectus referred to below. The offering and sale of the Shares contemplated by this underwriting agreement (this “Agreement”) is referred to herein as the “Offering.”
